IP Library › Granted Patent US 11,813,296
Granted Patent B2
US 11,813,296 · App. 16/593,469 · Granted Nov 14, 2023

Bacillus subtilis probiotics and methods of use for improving immune function, hormonal status, and physical performance

Inventors: John Deaton (Kennesaw, GA); Ana Maria Cuentas (Woodstock, GA)
Assignee: Deerland Enzymes, Inc.
A61K35/742A61K9/0053A61K2035/115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,813,296
App. No.
16/593,469
Granted
Nov 14, 2023
Kind
B2
Abstract

Methods of using Bacillus subtilis probiotic supplementation to promote lower circulating TNF-α in resistance trained males are presented. Methods of administering Bacillus subtilis probiotic supplementation to an athletic population in conjunction with a sound nutrition and training regimen are presented herein. College athletes typically undergo periods of elevated stress both physically and mentally which may negatively affect recovery and adaptation. 12-weeks of probiotic supplementation resulted in attenuated circulating TNF-α concentrations in college athletes following offseason training.

Claims (18)

1. A method of reducing tumor necrosis factor-alpha (TNF-α) in human serum, comprising the steps of:

(a) administering orally to a human a composition comprising Bacillus subtilis in a dose of from about 1·10 8 colony forming units (CFU) per day to about 1·10 11 CFU per day for about 12 weeks; and

(b) submitting the human to a resistance training program throughout the 12 weeks.

2. The method of claim 1 , wherein the resistance program includes workouts 2-3 times per week.

3. The method of claim 1 , further comprising the steps of measuring TNF-α in blood plasma of the human both before and after steps (a) and (b).

4. The method of claim 1 , wherein the composition comprises Bacillus subtilis in a dose of from about 1·10 9 CFU per day to about 1·10 10 CFU per day.

5. The method of claim 4 , wherein the TNF-α level is reduced by about 0.2 pg/mL in serum.

6. A method for treating or reducing inflammation in a human, comprising the steps of:

(a) administering orally to the human in need of such treatment a composition comprising Bacillus subtilis in a dose of from about 1·10 8 CFU per day to about 1·10 11 CFU per day for about 12 weeks, and

(b) measuring TNF-α in blood plasma of the human,

wherein the TNF-α level is reduced in serum.

7. The method of claim 6 , further comprising the step of:

(b) submitting the human to a resistance training program throughout the 12 weeks.

8. The method of claim 6 , wherein the composition comprises Bacillus subtilis in a dose of from about 1·10 9 CFU per day to about 1·10 10 CFU per day.

9. The method of claim 7 , wherein the composition comprises Bacillus subtilis in a dose of from about 1·10 9 CFU per day to about 1·10 10 CFU per day.

10. The method of claim 9 , wherein the resistance program includes workouts 2-3 times per week.

11. The method of claim 10 , further comprising the steps of measuring TNF-α in blood plasma of the human both before and after steps (a) and (b).

12. The method of claim 11 , wherein the TNF-α level is reduced by about 0.2 pg/mL in serum.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2021
From: DEATON, JOHN; CUENTAS, ANA MARIA
To: DEERLAND ENZYMES, INC.
Reel/Frame 055328/0291 →
Continuity (2)
Provisional Application 62741300 · Oct 4, 2018
Related Publication 20200108106A1 · Apr 9, 2020